NanoViricides Inc.
1 Controls Drive,
Shelton, CT 06484
Ph No:- 203-937-6137
Fax No:- 203-859-5095
Email:- info@nanoviricides.com
Welcome to NanoViricide's Investor Relations section.
NanoViricides, Inc. is a leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology permits direct attacks at multiple points on a virus particle. It is believed that such actions lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.
We have been aggressively expanding our portfolio of virus targets and drug candidates every year since our inception in May, 2005.
July 10, 2024
NanoViricides is leveraging its unique nanoviricide platform technology to create first-in-class drugs against viruses
May 7, 2023
EFHutton: NNVC- Inflection Point Reached of Multi-Indications Platform; Re-Initiating With a Buy and $6.50 Price Target
Dec. 13, 2023
EFHutton: NNVC- Inflection Point Reached of Multi-Indications Platform; Re-Initiating With a Buy and $6.50 Price Target
Most Recent Fact Sheet
Most Recent Fact Sheet
Nanoviricides Inc Fact Sheet: Sept. 8th, 2023
"PENICILLIN" FOR VIRUSES
Eradicating Diseases Caused by Viruses Using 21st Century Nanotechnology
Presented by: Eugene Seymour, MD, MPH
Chief Executive Officer
December - 2017
-
June 24, 2024 - A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
-
June 4, 2024 - This is NHP PK profile of NV-387 which showed desirable unusually slow decline
-
May 23, 2024 - NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
-
May 15, 2024 - NanoViricides Has Filed its Quarterly Report - NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection
-
May 10, 2024 - NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
-
April 30, 2024 - NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
-
February 15, 2024 - NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
-
January 4, 2024 - NanoViricides to Present at the Biotech Showcase in San Fransisco
-
November 28, 2023 - The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
-
November 15, 2023 - NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
-
November 14, 2023 - Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
-
October 11, 2023 - NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
August 21, 2023 - The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
-
July 11, 2023 - Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model
May 31, 2023 - NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
May 16, 2023 - NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
April 25, 2023 - NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
April 17, 2023 - NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
- 04-15-2014 NanoViricides won the IAIR AWARD
NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
- 02-20-2014Dr. Anil R. Diwan Recognized as "Researcher of the year".
NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as "Researcher of the Year" by BusinessNewHaven, a Connecticut Area Business Journal.
Quick Links
Contact Information
NanoViricides, Inc.
1 Controls Drive,
Shelton, CT 06484
Phone: +1-203-937-6137
Phone: +1-888-591-3579
Fax: +1-203-859-5095
E-mail: info@nanoviricides.com
